Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of ...

Four others are still undergoing treatment Even better, the drug, dostarlimab, has shown no side effects or downsides — unlike other treatments. “Radiation is effective in eliminating the ...

"They didn't believe me." They were given six months of treatment with an immunotherapy drug called dostarlimab, from the pharmaceutical company GlaxoSmithKline, which helped fund the research.

But in 2024, she published encouraging results from a small study of people with rectal cancer, in which all 42 patients who got the checkpoint inhibitor, dostarlimab, as a monthly infusion became ...

In a very small trial done by doctors at New York's Memorial Sloan Kettering Cancer Center, patients took a drug called dostarlimab for six months. The trial resulted in every single one of their ...

When she realized that the approach using only dostarlimab would be less harsh on her body, she quickly signed up. But the new study, published last week in the New England Journal of Medicine ...

Most study participants were able to avoid operations after taking dostarlimab. A new study in the New England Journal of Medicine suggests that some people with early stage cancers may be able to ...

Dostarlimab has been watched closely by oncologists since its trial on rectal cancer patients at Memorial Sloan Kettering Cancer Center. It eradicated patient tumors, and they've remained cancer-free.

Dostarlimab with platinum-based chemotherapy can be used as an option to treat primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in ...